RxDoctor Payments Data

Taslim Khattak, MD

Internal Medicine · Germantown, TNNPI 1679540298

Payments from drug & device makers

$1,760in general payments, 2019–2025

Across 59 payments — averaging $29.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$401
  • Novo Nordisk$310
  • Madrigal Pharmaceuticals$150
  • Boehringer Ingelheim$130
  • Intercept Pharmaceuticals, Inc.$125
  • Boston Scientific$107
  • plus $537 from 16 others

What the payments were for

  • Food & beverage$1,760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,760 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$40,217
Medicare patients
96
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$75,337
OzempicSemaglutide24$57,391
LinzessLinaclotide39$49,411
EliquisApixaban35$45,922
JardianceEmpagliflozin34$42,311
TrulicityDulaglutide16$31,138
TradjentaLinagliptin21$24,741
FarxigaDapagliflozin Propanediol11$14,563
KerendiaFinerenone15$14,339
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$5,989
Potassium Chloride149$4,897
Duloxetine Hcl96$3,757
Atorvastatin Calcium309$3,336
Albuterol Sulfate HfaAlbuterol Sulfate84$3,187
Rosuvastatin Calcium172$2,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$26$106,47587 claims
Boehringer IngelheimJardiance, Tradjenta$130$67,05255 claims
Novo NordiskOzempic$310$57,39124 claims
PfizerEliquis$32$45,92235 claims
AstraZenecaFarxiga$88$14,56311 claims
BayerKerendia$15$14,33915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →